CytoMed Therapeutics Ltd., a Singapore-based clinical stage biopharmaceutical company, announced that it has sufficient resources to fund its activities for at least the next year, supported by its low-cost infrastructure in Southeast Asia. The company is exploring additional funding options including licensing, asset monetisation from real estate properties, and long-term strategic partnerships with biotechs and hospitals. CytoMed’s Chairman, Peter Choo, intends to increase his shareholding in the company and will make a formal announcement accordingly. CytoMed has diversified its product pipeline through its new subsidiary, LongevityBank, by developing clinical-grade cord blood-derived Natural Killer (NK) cells, with support from Enterprise Singapore. The company is also advancing clinical trials for its allogeneic unmodified Gamma Delta (γδ) T cells (CTM-GDT) in collaboration with Universiti Malaya, targeting a first-in-human Phase I trial for no-option cancer patients in Malaysia, with plans to submit an Investigational New Drug application before June. Additionally, its ongoing Phase I CAR-T cell clinical trial at National University Hospital Singapore has treated six patients at two dosage levels across various cancer types. CytoMed was ranked 4 out of 5 points for investment potential in Morning Star’s December 2025 publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624581-en) on January 13, 2026, and is solely responsible for the information contained therein.